1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Ventricular Fibrillation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, KE; Curtis, MJ | 2 |
| Baker, KE; Curtis, MJ; Whittaker, M; Wood, LM | 1 |
| Inada, M; Iwasaka, T; Izuoka, T; Kimura, Y; Kitashiro, S; Tamura, K; Tamura, T; Tsuji, H | 1 |
| Ansley, DM; English, JC; Godin, DV; Kim, CW; Lee, JU; Loucks, EB; Qayumi, AK | 1 |
| Auchampach, JA; Cavero, I; Gross, GJ; Pieper, GM | 1 |
| Leong, LL; Papadimitriou, JM; Stephens, CJ; Sturm, MJ; Taylor, RR | 1 |
| Braquet, C; Köpernik, W; Mest, HJ; Rein, T; Riedel, A | 1 |
| Flores, NA; Sheridan, DJ | 1 |
| Bigaud, M; Parratt, JR; Wainwright, CL | 1 |
10 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Ventricular Fibrillation
| Article | Year |
|---|---|
Left regional cardiac perfusion in vitro with platelet-activating factor, norepinephrine and K+ reveals that ischaemic arrhythmias are caused by independent effects of endogenous "mediators" facilitated by interactions, and moderated by paradoxical antago
Topics: Animals; Azepines; Coronary Vessels; Heart Ventricles; In Vitro Techniques; Male; Myocardial Ischemia; Norepinephrine; Perfusion; Platelet Activating Factor; Potassium; Rats; Rats, Wistar; Triazoles; Ventricular Fibrillation; Ventricular Function | 2004 |
Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?
Topics: Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Electrocardiography; Leucine; Male; Platelet Activating Factor; Rats; Rats, Wistar; Sulfonamides; Ventricular Fibrillation | 2006 |
The effect of platelet-activating-factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Dogs; Electrocardiography; Isoquinolines; Myocardial Contraction; Myocardial Reperfusion Injury; Platelet Activating Factor; Pyridinium Compounds; Tachycardia, Ventricular; Tetrahydroisoquinolines; Ventricular Fibrillation; Ventricular Function, Left | 1994 |
The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
Topics: Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Cardiac Output; Cardiac Volume; Disease Models, Animal; Female; Heart Arrest; Hemodynamics; Isoquinolines; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Platelet Activating Factor; Platelet Aggregation Inhibitors; Pyridinium Compounds; Random Allocation; Stroke Volume; Swine; Tetrahydroisoquinolines; Ventricular Fibrillation; Ventricular Function | 1998 |
Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function.
Topics: Animals; Coronary Circulation; Dogs; Dose-Response Relationship, Drug; Female; Free Radicals; Incidence; Male; Myocardial Infarction; Myocardial Ischemia; Myocardium; Neutrophils; Peroxidase; Platelet Activating Factor; Pyridines; Reperfusion Injury; Thiazoles; Ventricular Fibrillation | 1998 |
Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves an ischaemia-selective mechanism.
Topics: Animals; Anti-Arrhythmia Agents; Azepines; Disease Models, Animal; Male; Myocardial Ischemia; Perfusion; Platelet Activating Factor; Protective Agents; Rats; Rats, Wistar; Triazoles; Vasodilation; Ventricular Fibrillation | 1999 |
The effects of a PAF antagonist on ischemic myocardial damage and arrhythmia in the dog.
Topics: Animals; Arrhythmias, Cardiac; Azepines; Coronary Disease; Dogs; Myocardial Reperfusion Injury; Platelet Activating Factor; Tachycardia; Triazoles; Ventricular Fibrillation | 1992 |
Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Azepines; Clemastine; Coronary Disease; Coronary Vessels; Guinea Pigs; Organoselenium Compounds; Ouabain; Piperidines; Platelet Activating Factor; Propranolol; Rats; Triazoles; Umbelliferones; Ventricular Fibrillation | 1992 |
Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Electrophysiology; Guinea Pigs; Heart; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Perfusion; Platelet Activating Factor; Ventricular Fibrillation | 1990 |
The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion.
Topics: Acute Disease; Animals; Blood Gas Analysis; Cardiac Complexes, Premature; Coronary Disease; Disease Models, Animal; Diterpenes; Dogs; Drug Evaluation, Preclinical; Electrocardiography; Ginkgolides; Hemodynamics; Hydrogen-Ion Concentration; Lactones; Myocardial Reperfusion; Oxygen; Platelet Activating Factor; Platelet Count; Quinolinium Compounds; Random Allocation; Tachycardia; Time Factors; Ventricular Fibrillation | 1989 |